Nelipepimut-S, an advanced peptide-based immunotherapeutic intervention, has demonstrated significant efficacy within the biomedical sector as it pertains to breast cancer management. Acting with precision, it selectively engages HER2-positive malignancies, thereby amplifying and fortifying the immune system's retaliation against these deleterious cells.
CAT No: R2072
CAS No:160212-35-1
Synonyms/Alias:NELIPEPIMUT-S;Neuvax;160212-35-1;NeuVax vaccine;KIFGSLAFL;Nelipepimut-S [USAN];E75 peptide;UNII-7M0A29CD8B;7M0A29CD8B;DTXSID80166835;L-Leucine, L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L-phenylalanyl-;(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid;Nelipepimut-S (USAN);L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L-phenylalanyl-L-leucine;Human receptor tyrosine-protein kinase erbB-2 (proto-oncogene Neu, tyrosine kinase- type cell surface receptor HER2, CD340)-(347-355)-peptide;Nelipepimut s;E75 HER2 peptide;E-75 PEPTIDE;10: PN: WO2015050181 SEQID: 10 claimed protein;CHEMBL386200;NELIPEPIMUT S [WHO-DD];DTXCID3089326;AHOKKYCUWBLDST-QYULHYBRSA-N;CHEBI:230310;Her2 369-377;BDBM50409332;AKOS040753235;DA-76075;E-75;HER-2/NEU PEPTIDE (369-377);HY-106204;CS-0025241;Q27268544;HUMAN RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (PROTO-ONCOGENE NEU, TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER2, CD340)-(347-355)-PEPTIDE;
Chemical Name:(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
Nelipepimut-S is a synthetic peptide antigen derived from the HER2/neu protein, specifically designed to mimic an immunodominant epitope of the HER2/neu (ERBB2) proto-oncogene. As a peptide compound, it holds significant interest in the field of cancer immunology and peptide-based research due to its capacity to elicit targeted immune responses against cells expressing the HER2/neu antigen. The molecule's structure and sequence specificity have made it a valuable tool for investigating peptide-mediated immune mechanisms, T-cell activation, and antigen presentation. Its relevance is underscored by its integration into studies seeking to unravel the molecular underpinnings of tumor-associated antigen recognition and the development of novel immunotherapeutic strategies.
Epitope Mapping: Nelipepimut-S is widely utilized in studies aimed at mapping immunogenic epitopes within the HER2/neu protein. By serving as a defined peptide sequence corresponding to a known immunodominant region, it enables researchers to dissect the specificity and breadth of T-cell responses to HER2/neu. This application is particularly valuable for elucidating which regions of the protein are most effective in stimulating CD8+ cytotoxic T lymphocytes, thereby informing the rational design of next-generation peptide antigens and immunological assays.
Immunogenicity Assessment: The peptide is frequently employed in in vitro and ex vivo immunogenicity studies to assess the capacity of antigen-presenting cells to process and present HER2/neu-derived epitopes. By introducing Nelipepimut-S into cell-based assays, investigators can monitor the activation, proliferation, and cytokine secretion profiles of T-cell populations. This approach provides critical insights into the molecular mechanisms governing antigen recognition, T-cell priming, and immune repertoire diversity, which are fundamental for advancing peptide vaccine research and immune monitoring protocols.
Peptide-MHC Binding Studies: Nelipepimut-S serves as a model substrate for evaluating the binding affinity and stability of peptide-MHC class I complexes. Its defined sequence allows for precise quantification of peptide-HLA interactions, facilitating the development of high-throughput screening assays and computational models that predict epitope presentation. Such studies are instrumental in optimizing peptide design for enhanced immunogenicity and in validating the functional relevance of HER2/neu as a target for immune-based interventions.
T-Cell Functional Assays: The compound is integral to the development and standardization of T-cell functional assays, including cytotoxicity, proliferation, and cytokine release assays. By providing a consistent and well-characterized peptide antigen, it enables rigorous evaluation of T-cell responses in research settings. These assays are essential for characterizing the efficacy of peptide-based immunomodulators, understanding T-cell receptor specificity, and benchmarking immune response metrics in preclinical studies.
Peptide Synthesis and Analytical Reference: Nelipepimut-S is also employed as a reference standard in peptide synthesis and analytical characterization workflows. Its well-defined structure and immunological relevance make it suitable for validating synthetic protocols, calibrating analytical instruments, and benchmarking peptide purity and identity in quality control laboratories. This application supports the advancement of peptide manufacturing technologies and ensures reproducibility in research involving HER2/neu-targeted peptide antigens.
2. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
3. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
5. Emu oil in combination with other active ingredients for treating skin imperfections
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More